Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study

Area of Science:

• Pharmacology
• Infectious Diseases
• Drug Delivery Systems

Background:

• Published in vitro data supports intermittent infusions of ceftolozane-tazobactam.
• Current outpatient antimicrobial therapy services often limit infusion frequency to once or twice daily.
• This limitation poses challenges for delivering ceftolozane-tazobactam via short infusions in ambulatory settings.

Purpose of the Study:

• To evaluate the stability of ceftolozane-tazobactam in elastomeric infusion devices for continuous infusion.
• To assess the impact of time, temperature, and concentration on stability within clinically relevant ranges for outpatient settings.

Main Methods:

• Ceftolozane-tazobactam was prepared in elastomeric infusion devices (240 mL) at concentrations simulating renal, standard, and high daily doses.
• Devices were incubated at room temperature (25°C) and body temperature (37°C), with sampling over 48 hours.
• Refrigerated devices (4°C) were sampled over 10 days, and drug concentrations were quantified using ultra-high performance liquid chromatography.

Main Results:

• Ceftolozane demonstrated stability above 90% at 24 hours, even at 37°C.
• Tazobactam exhibited greater stability than ceftolozane at 37°C.
• Minimal degradation of both components was observed at 4°C over 7 days.

Conclusions:

• Ceftolozane-tazobactam is chemically stable for continuous infusion in elastomeric devices.
• This formulation is suitable for use in ambulatory care settings.
• The findings support the use of ceftolozane-tazobactam for extended continuous infusions in outpatient antimicrobial therapy.